{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:17:19Z","timestamp":1761765439884,"version":"3.44.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.urology.2011.03.033","type":"journal-article","created":{"date-parts":[[2011,8,6]],"date-time":"2011-08-06T14:26:39Z","timestamp":1312640799000},"page":"380-385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Prostate Cancer Gene 3 Score Predicts Prostate Biopsy Outcome in Men Receiving Dutasteride for Prevention of Prostate Cancer: Results From the REDUCE Trial"],"prefix":"10.1016","volume":"78","author":[{"given":"Sheila M.J.","family":"Aubin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Sarno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Blase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Aussie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Rittenhouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger S.","family":"Rittmaster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald L.","family":"Andriole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Groskopf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2011.03.033_bib1","first-page":"5975","article-title":"DD3: a new prostate-specific gene, highly over-expressed in prostate cancer","volume":"59","author":"Bussemakers","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2011.03.033_bib2","first-page":"2695","article-title":"DD3PCA3, a very sensitive and specific marker to detect prostate tumors","volume":"62","author":"De Kok","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2011.03.033_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0302-2838(03)00201-X","article-title":"DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer","volume":"44","author":"Hessels","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2011.03.033_bib4","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1373\/clinchem.2005.063289","article-title":"APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer","volume":"52","author":"Groskopf","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.urology.2011.03.033_bib5","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.urology.2006.12.014","article-title":"PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy","volume":"69","author":"Marks","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urology.2011.03.033_bib6","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.eururo.2008.06.071","article-title":"Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy","volume":"54","author":"Haese","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2011.03.033_bib7","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.juro.2007.11.038","article-title":"PCA3: a molecular urine assay for predicting prostate biopsy outcome","volume":"179","author":"Deras","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2011.03.033_bib8","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.juro.2008.01.013","article-title":"PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance","volume":"179","author":"Nakanishi","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2011.03.033_bib9","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.juro.2010.06.098","article-title":"PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial","volume":"184","author":"Aubin","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2011.03.033_bib10","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1586\/14737140.8.7.1073","article-title":"The REDUCE trial: chemoprevention in prostate cancer using a dual 5-alpha reductase inhibitor, dutasteride","volume":"8","author":"Musquera","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.urology.2011.03.033_bib11","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/pros.21011","article-title":"Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study","volume":"69","author":"van Gils","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.urology.2011.03.033_bib12","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1097\/01.ju.0000139320.78673.2a","article-title":"Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial","volume":"172","author":"Andriole","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2011.03.033_bib13","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2011.03.033_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2007.11.003","article-title":"A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy","volume":"389","author":"Sokoll","year":"2008","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.urology.2011.03.033_bib15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver-operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/j.urology.2011.03.033_bib16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0090-4295(03)00759-3","article-title":"New targets for therapy in prostate cancer: differential display code 3 (DD3PCA3), a highly prostate cancer-specific gene","volume":"62","author":"Schalken","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.urology.2011.03.033_bib17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/sj.pcan.4500936","article-title":"Androgen receptor and prostate cancer","volume":"10","author":"Richter","year":"2007","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urology.2011.03.033_bib18","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1158\/0008-5472.CAN-06-3332","article-title":"Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer","volume":"67","author":"Mostaghel","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2011.03.033_bib19","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.urology.2008.01.025","article-title":"Does the level of prostate cancer risk affect cancer prevention with finasteride?","volume":"71","author":"Thompson","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.urology.2011.03.033_bib20","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/jnci\/djm117","article-title":"Finasteride and high-grade prostate cancer in the prostate cancer prevention trial","volume":"99","author":"Lucia","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2011.03.033_bib21","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/1940-6207.CAPR-08-0092","article-title":"Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach","volume":"1","author":"Redman","year":"2008","journal-title":"Cancer Prev Res"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429511003475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429511003475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:56:18Z","timestamp":1758765378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429511003475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0090429511003475"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2011.03.033","relation":{},"ISSN":["0090-4295"],"issn-type":[{"type":"print","value":"0090-4295"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate Cancer Gene 3 Score Predicts Prostate Biopsy Outcome in Men Receiving Dutasteride for Prevention of Prostate Cancer: Results From the REDUCE Trial","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2011.03.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}